Aptose Biosciences (TSE:APS) Share Price Crosses Above 50-Day Moving Average – What’s Next?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$2.31 and traded as high as C$2.33. Aptose Biosciences shares last traded at C$2.33, with a volume of 5,800 shares changing hands.

Aptose Biosciences Trading Up 5.9%

The stock has a market cap of C$5.95 million, a P/E ratio of -0.22 and a beta of -1.38. The company has a debt-to-equity ratio of -98.74, a quick ratio of 5.41 and a current ratio of 0.55. The stock’s fifty day moving average is C$2.31 and its 200 day moving average is C$2.24.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported C($4.16) earnings per share for the quarter. As a group, equities research analysts predict that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.